ArticleJournal of clinical medicine2021

Real-World Incidence of Immune-Related Adverse Events Associated with Nivolumab Plus Ipilimumab in Patients with Advanced Renal Cell Carcinoma: A Retrospective Observational Study.

Satoshi Washino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.